TPKII phosphorylates serines 202 and 404.
GSK-3β transfection phosphorylates serines 199, 202,
235, 396, 404 and 413, and threonines 205 and 231.
These sites are among the major abnormal
phosphorylation
using
as immunogen a synthetic phosphopeptide derived
from the region of tau that contains serine 396. The
serum is affinity purified using epitope-specific affinity
chromatography. The antibody is preadsorbed
TPKII phosphorylates serines 202 and 404.
GSK-3β transfection phosphorylates serines 199, 202,
235, 396, 404 and 413, and threonines 205 and 231.
These sites are among the major abnormal
phosphorylation
TPKII phosphorylates serines 202 and 404.
GSK-3β transfection phosphorylates serines 199, 202,
235, 396, 404 and 413, and threonines 205 and 231.
These sites are among the major abnormal
phosphorylation
TPKII phosphorylates
serines 202 and 404. GSK-3β transfection
phosphorylates serines 199, 202, 235, 396, 404 and
413, and threonines 205 and 231.
These sites are among the major abnormal
phosphorylation
TPKII phosphorylates serines 202 and 404.
GSK-3β transfection phosphorylates serines 199, 202,
235, 396, 404 and 413, and threonines 205 and 231.
These sites are among the major abnormal
phosphorylation
TPKII phosphorylates serines 202 and 404.
GSK-3β transfection phosphorylates serines 199, 202,
235, 396, 404 and 413, and threonines 205 and 231.
These sites are among the major abnormal phosphory-
lation
TPKII phosphorylates serines 202 and 404.
GSK-3β transfection phosphorylates serines 199, 202,
235, 396, 404 and 413, and threonines 205 and 231.
These sites are among the major abnormal
phosphorylation
TPKII phosphorylates serines 202 and 404.
GSK-3β transfection phosphorylates serines 199, 202,
235, 396, 404 and 413, and threonines 205 and 231.
These sites are among the major abnormal
phosphorylation
TPKII phosphorylates serines 202 and 404.
GSK-3β transfection phosphorylates serines 199, 202,
235, 396, 404 and 413, and threonines 205 and 231.
These sites are among the major abnormal
phosphorylation
TPKII phosphorylates serines 202 and 404.
GSK-3β transfection phosphorylates serines 199, 202,
235, 396, 404 and 413, and threonines 205 and 231.
These sites are among the major abnormal
phosphorylation
phosphorylates serines 202 and 404.
GSK-3β transfection phosphorylates serines 199, 202,
235, 396, 404 and 413, and threonines 205 and 231.
These sites are among the major abnormal
phosphorylation
TPKII phosphorylates serines 202 and 404.
GSK-3β transfection phosphorylates serines 199, 202,
235, 396, 404 and 413, and threonines 205 and 231.
These sites are among the major abnormal
phosphorylation
Centaurin ?4 A4227 50807 ASAP1 P NP_060952.2 y y y
738 ε-Tubulin T1323 51175 TUBE1 M NP_057346.1 y y n/d
396 KCNK9 (TASK-3) K0514 51305 KCNK9 M NP_057685.1 y n/d n/d
745 TWEAK Receptor/Fn-14 T9700 51330 TNFRSF12A
Anti-PUMA, C-terminus H M WB Rb 50 µL AB4510 $195
Raf
Anti-Raf-1 H WB IPK Rb IgG 200 µg 07-396 $319
Anti-B-Raf H M R WB IPK Rb IgG 200 µg 07-453 $319
Anti-B-Raf, NT H
Centaurin ?4 A4227 50807 ASAP1 P NP_060952.2 y y y
738 ε-Tubulin T1323 51175 TUBE1 M NP_057346.1 y y n/d
396 KCNK9 (TASK-3) K0514 51305 KCNK9 M NP_057685.1 y n/d n/d
745 TWEAK Receptor/Fn-14 T9700 51330 TNFRSF12A
Centaurin ?4 A4227 50807 ASAP1 P NP_060952.2 y y y
738 ε-Tubulin T1323 51175 TUBE1 M NP_057346.1 y y n/d
396 KCNK9 (TASK-3) K0514 51305 KCNK9 M NP_057685.1 y n/d n/d
745 TWEAK Receptor/Fn-14 T9700 51330 TNFRSF12A
394 c-Jun N-Terminal Kinase J4500 P y y y
395 JNK, Activated (Diphosphorylated JNK) J4750 M y y y
396 KCNK9 (TASK-3) K0514 M y n/d n/d
397 Kaiso K4263 M y y y
398 KIF17 K3638 P n/d y y
399 KIF3A K3513
phospho-Ser 621) H M WB Pur 04-306
Polyclonal Antibody
Anti-Raf-1 H IPK WB Pur Rb IgG 200 µg 07-396
Anti-B-Raf H M R IPK WB Pur Rb IgG 200 µg 07-453
Anti-B-Raf, NT H M R
Diphosphorylated JNK) J4750 5599, 26419, 116554 Mapk8,MAPK8 NP_620637.1,NP_057909.1,XP_341400.3 M y y y
396 KCNK9 (TASK-3) K0514 51305 KCNK9 NP_057685.1 M y n/d n/d
397 Kaiso K4263 501506, 56805, 10009 Zbtb33